U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease
NORTH CHICAGO, Ill., Sept. 28, 2026 // -- AbbVie (NYSE:ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved JUVMO™ (tavapadon) tablets as the first and only selective D1/D5 receptor agonist for the treatment of adults with Parkinson's disease, a progressive…